after enrollment, the study assigns the participant to receive either mk-1045 (test drug) or blinatumomab (comparator). the assignment is done by the study system and is not chosen by the participant.

the assigned medication is given by intravenous infusion, which means the drug is delivered directly into a vein through a needle.

if the participant receives mk-1045, the infusion is a solution for infusion prepared according to the study protocol. the exact volume is expressed as a percentage (v/v) and is defined by the protocol.

if the participant receives blinatumomab, the dose is 28 µg (micrograms) per infusion, administered intravenously as described in the protocol.

the infusion is performed at the study site on the scheduled day for the first cycle.

the participant undergoes laboratory tests and clinical checks to evaluate safety and any side effects (adverse events).

any symptoms or problems are recorded and reported to the study team.

the participant may receive additional supportive care if needed, as allowed by the protocol.

the participant returns for the next intravenous infusion of the same medication, following the same dose and method as in cycle 1.

the timing of the second cycle follows the schedule defined by the study, typically after a set interval from the first infusion.

repeat laboratory tests and clinical assessments are performed to check for safety, side effects, and early signs of response.

the participant continues to report any new or worsening symptoms.

a third intravenous infusion of the assigned drug is given, using the same dose and administration method as in the previous cycles.

laboratory and clinical evaluations are repeated to assess safety and to determine whether the participant has achieved complete remission (the disappearance of disease signs) within the first three cycles.

any adverse events are documented.

after the three cycles, the study evaluates the primary outcome of complete remission and records the number of participants with adverse events or who discontinue treatment because of adverse events.

the assessment follows the definitions set out in the study protocol.

participants continue to be followed for overall survival and any long‑term side effects as defined by the study.

regular check‑ups and laboratory tests are performed according to the schedule in the protocol.